Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Operating Leases (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Operating Leases data on record, last reported at $123827.0 in Q4 2025.

  • For Q4 2025, Operating Leases fell 76.6% year-over-year to $123827.0; the TTM value through Dec 2025 reached $123827.0, down 76.6%, while the annual FY2025 figure was $305755.0, 52.59% down from the prior year.
  • Operating Leases reached $123827.0 in Q4 2025 per INM's latest filing, down from $215478.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $825427.0 in Q4 2021 and bottomed at $15994.0 in Q2 2023.
  • Average Operating Leases over 5 years is $397079.2, with a median of $347626.5 recorded in 2022.
  • Peak YoY movement for Operating Leases: plummeted 95.89% in 2023, then skyrocketed 3931.92% in 2024.
  • A 5-year view of Operating Leases shows it stood at $825427.0 in 2021, then tumbled by 77.72% to $183902.0 in 2022, then skyrocketed by 336.53% to $802784.0 in 2023, then plummeted by 34.07% to $529248.0 in 2024, then tumbled by 76.6% to $123827.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $123827.0 in Q4 2025, $215478.0 in Q3 2025, and $305755.0 in Q2 2025.